Handa Pharmaceuticals (6620.TWO) Earnings Analysis

Handa Pharmaceuticals (6620.TWO) next reports earnings on 2026-08-19, consensus EPS 0.285 TWD. Last quarter (2026-05-07) it beat with EPS 0.4577 TWD vs 0.43 TWD est (+6.4%). It has beaten estimates in 2/2 recent quarters (100%). Trailing P/E 20.68.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 6620.TWO next report earnings?

Next earnings date2026-08-19
Consensus EPS estimate0.285 TWD
Revenue estimate0.21B

6620.TWO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-070.4577 TWD0.43 TWD+6.4%Beat
2026-03-121.12 TWD0.43 TWD+160.5%Beat

Beat rate: 2/2 (100%) over reported quarters with consensus data.

6620.TWO valuation and analyst view

Trailing P/E20.68
Trailing EPS3.876 TWD
Price / book2.66
Dividend yield2.45%
Market cap14.47B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Handa Pharmaceuticals (6620.TWO)'s next earnings date?

Handa Pharmaceuticals is next scheduled to report on 2026-08-19, with a consensus EPS estimate of 0.285 TWD and revenue estimate of 0.21B.

Did 6620.TWO beat earnings last quarter?

In its 2026-05-07 report, 6620.TWO posted EPS of 0.4577 TWD versus a 0.43 TWD estimate — a beat of 6.4%.

What is 6620.TWO's earnings track record?

Over the last 2 reported quarters with consensus data, 6620.TWO beat estimates 2 times (100%).

What is 6620.TWO's current P/E ratio and EPS?

6620.TWO trades at a trailing P/E of 20.68 on trailing EPS of 3.875933089136036 TWD.

What do analysts rate 6620.TWO?

6620.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.